biologic

Zomacton

somatropin

Loss of exclusivityJanuary 2014projected — 12-year biologic exclusivity estimate
CompanyFerring PharmaceuticalsSee this company's full patent-cliff portfolio

Drug detail

Brand nameZomacton
Active ingredientsomatropin
Strength5MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2002
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zomacton patent cliff — loss of exclusivity January 2014 | CliffBio